세계의 인간화 마우스 및 쥐 모델 시장 : 유형, 용도, 최종 사용자별 예측(2025-2030년)

The Humanized Mouse & Rat Model Market was valued at USD 257.38 million in 2023, expected to reach USD 275.91 million in 2024, and is projected to grow at a CAGR of 7.33%, to USD 422.57 million by 2030.

The humanized mouse and rat model market is an integral segment of biomedical research, geared towards developing and testing viable therapeutic strategies for complex human diseases. This scope encompasses genetically engineered rodents that carry functioning human genes, tissues, or cells, providing an in-vivo model conforming to human biological and pathological phenomena. The necessity for these models is profound in understanding disease mechanisms, drug discovery, and personalized medicine, extending to applications in oncology, immunology, and infectious diseases. End-use domains stretch across academic and research institutions, pharmaceutical and biotechnology companies, and contract research organizations.

Key growth factors include the increasing prevalence of chronic diseases, the urgency for novel therapeutic solutions, and advancing genomic technologies enhancing model development. Simultaneously, ethical concerns and high costs challenge market expansion. Opportunities arise from ongoing innovations in CRISPR and other gene-editing technologies, which potentially reduce development times and costs while increasing the precision of genetic humanization, allowing organizations to advance drug testing with higher reliability. However, market players must navigate stringent regulatory frameworks and overcome technical hurdles associated with humanizing complex genetic and immunological traits of rodents.

Innovations lie in enhancing model sophistication through multi-gene humanization and integrating human immune components, offering improved insights into human-specific responses to therapies. Collaborative synergies among academic, clinical, and industrial sectors would catalyze enhanced model platforms, accelerating translational research. For market players, a strategic focus on building portfolios of more comprehensive and highly specialized humanized models can unlock competitive advantages. Additionally, participating in partnerships leveraging AI and computational models could revolutionize predictive analytics, thus maximizing model utility in drug discovery.

In conclusion, while promising opportunities exist, stakeholders must leverage technological advancements and strategic collaborations to mitigate prevailing obstacles, thus ensuring sustained market growth and fulfilling the growing demand for effective human translational systems in biomedical research.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Humanized Mouse & Rat Model Market

The Humanized Mouse & Rat Model Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing number of biomedical research and drug development activities
  • Emerging focus toward personalized medicine and precision therapeutics
  • Rising demand owing to regulatory requirements and ethical considerations
• Market Restraints
  • Complex model development and validation process of humanized mouse & rats
• Market Opportunities
  • Growing advancements in genetic engineering technologies
  • Integration of human organoids and organ-on-a-chip technologies with humanized mouse and rat models
• Market Challenges
  • Limitations in recapitulating human physiology

Porter's Five Forces: A Strategic Tool for Navigating the Humanized Mouse & Rat Model Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Humanized Mouse & Rat Model Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Humanized Mouse & Rat Model Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Humanized Mouse & Rat Model Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Humanized Mouse & Rat Model Market

A detailed market share analysis in the Humanized Mouse & Rat Model Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Humanized Mouse & Rat Model Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Humanized Mouse & Rat Model Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Humanized Mouse & Rat Model Market

A strategic analysis of the Humanized Mouse & Rat Model Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Humanized Mouse & Rat Model Market, highlighting leading vendors and their innovative profiles. These include Aragen Life Sciences, Beijing Vitalstar Biotechnology Co., Ltd., BIOCYTOGEN, Champions Oncology, Inc., Charles River Laboratories International, Inc., Crown Bioscience, Inc., Cyagen US Inc., GemPharmatech, genOway, Harbour BioMed, Hera BioLabs, inGenious Targeting Laboratory, Inc., Oncodesign Precision Medicine, Ozgene Pty Ltd., Pharmatest Services Oy, Taconic Biosciences, Inc., The Jackson Laboratory, TransCure Bioservices, and Vivo Bio Tech Ltd..

Market Segmentation & Coverage

This research report categorizes the Humanized Mouse & Rat Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Humanized Mouse Model and Humanized Rat Model. The Humanized Mouse Model is further studied across BLT Model, Hu-PBL-scid Model, and Hu-SRC-scid Model.
• Based on Application, market is studied across Hematopoiesis, Immunology & Infectious Diseases, Neuroscience, Oncology, and Toxicology.
• Based on End-User, market is studied across Academic & Research Facilities, Contract research & Manufacturing Organizations, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing number of biomedical research and drug development activities
    • 5.1.1.2. Emerging focus toward personalized medicine and precision therapeutics
    • 5.1.1.3. Rising demand owing to regulatory requirements and ethical considerations
  • 5.1.2. Restraints
    • 5.1.2.1. Complex model development and validation process of humanized mouse & rats
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing advancements in genetic engineering technologies
    • 5.1.3.2. Integration of human organoids and organ-on-a-chip technologies with humanized mouse and rat models
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations in recapitulating human physiology
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Humanized Mouse & Rat Model Market, by Type

• 6.1. Introduction
• 6.2. Humanized Mouse Model
  • 6.2.1. BLT Model
  • 6.2.2. Hu-PBL-scid Model
  • 6.2.3. Hu-SRC-scid Model
• 6.3. Humanized Rat Model

7. Humanized Mouse & Rat Model Market, by Application

• 7.1. Introduction
• 7.2. Hematopoiesis
• 7.3. Immunology & Infectious Diseases
• 7.4. Neuroscience
• 7.5. Oncology
• 7.6. Toxicology

8. Humanized Mouse & Rat Model Market, by End-User

• 8.1. Introduction
• 8.2. Academic & Research Facilities
• 8.3. Contract research & Manufacturing Organizations
• 8.4. Pharmaceutical & Biotechnology Companies

9. Americas Humanized Mouse & Rat Model Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Humanized Mouse & Rat Model Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Humanized Mouse & Rat Model Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aragen Life Sciences
• 2. Beijing Vitalstar Biotechnology Co., Ltd.
• 3. BIOCYTOGEN
• 4. Champions Oncology, Inc.
• 5. Charles River Laboratories International, Inc.
• 6. Crown Bioscience, Inc.
• 7. Cyagen US Inc.
• 8. GemPharmatech
• 9. genOway
• 10. Harbour BioMed
• 11. Hera BioLabs
• 12. inGenious Targeting Laboratory, Inc.
• 13. Oncodesign Precision Medicine
• 14. Ozgene Pty Ltd.
• 15. Pharmatest Services Oy
• 16. Taconic Biosciences, Inc.
• 17. The Jackson Laboratory
• 18. TransCure Bioservices
• 19. Vivo Bio Tech Ltd.